DrugPatentWatch Database Preview
Details for Patent: 8,158,156
Which drugs does patent 8,158,156 protect, and when does it expire?
This patent has thirty-four patent family members in twenty-one countries.
Summary for Patent: 8,158,156
Title: | Abuse-deterrent multi-layer pharmaceutical composition comprising an opioid antagonist and an opioid agonist |
Abstract: | Provided herein is a pharmaceutical composition comprising an antagonist, an agonist, a seal coat, and a sequestering polymer, wherein the antagonist, agonist, seal coat and at least one sequestering polymer are all components of a single unit, and wherein the seal coat forms a layer physically separating the antagonist from the agonist from one another. Methods for manufacturing such a pharmaceutical composition are also provided. |
Inventor(s): | Matthews; Frank (Edison, NJ), Boehm; Garth (Westfield, NJ), Tang; Lijuan (Flemington, NJ), Liang; Alfred (Edison, NJ) |
Assignee: | Alpharma Pharmaceuticals, LLC (Bridgewater, NJ) |
Application Number: | 11/820,499 |
Patent Claim Types: see list of patent claims | Use; Composition; Formulation; |
Drugs Protected by US Patent 8,158,156
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Patent Submitted |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Alpharma Pharms | EMBEDA | morphine sulfate; naltrexone hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 022321-001 | Aug 13, 2009 | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG TERM OPIOID TREATEMENT BY ORALLY ADMINISTERING AN INTACT COMPOSITION AS CLAIMED. | ➤ Sign Up | ||||
Alpharma Pharms | EMBEDA | morphine sulfate; naltrexone hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 022321-002 | Aug 13, 2009 | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG TERM OPIOID TREATEMENT BY ORALLY ADMINISTERING AN INTACT COMPOSITION AS CLAIMED. | ➤ Sign Up | ||||
Alpharma Pharms | EMBEDA | morphine sulfate; naltrexone hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 022321-003 | Aug 13, 2009 | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG TERM OPIOID TREATEMENT BY ORALLY ADMINISTERING AN INTACT COMPOSITION AS CLAIMED. | ➤ Sign Up | ||||
Alpharma Pharms | EMBEDA | morphine sulfate; naltrexone hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 022321-004 | Aug 13, 2009 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG TERM OPIOID TREATEMENT BY ORALLY ADMINISTERING AN INTACT COMPOSITION AS CLAIMED. | ➤ Sign Up | ||||
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Patent Submitted |
Non-Orange Book US Patents Family Members for Patent 8,158,156
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
Patent No. | Title | Estimated Patent Expiration |
---|---|---|
8,846,104 | Pharmaceutical compositions for the deterrence and/or prevention of abuse | ➤ Sign Up |
8,877,247 | Abuse-deterrent multi-layer pharmaceutical composition comprising an opioid antagonist and an opioid agonist | ➤ Sign Up |
7,682,633 | Pharmaceutical composition | ➤ Sign Up |
7,682,634 | Pharmaceutical compositions | ➤ Sign Up |
Patent No. | Title | Estimated Patent Expiration |
International Family Members for US Patent 8,158,156
Country | Document Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Cyprus | 1112868 | ➤ Sign Up | |||
Canada | 2655835 | ➤ Sign Up | |||
China | 101677963 | ➤ Sign Up | |||
Cyprus | 1118077 | ➤ Sign Up | |||
Country | Document Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |